Thera-SAbDab

FORALUMAB

>   Structural Summary
TherapeuticForalumab
TargetCD3E
Heavy ChainQVQLVESGGGVVQPGRSLRLSCAASGFKFSGYGMHWVRQAPGKGLEWVAVIWYDGSKKYYVDSVKGRFTISRDNSKNTLYLQMNSLRAEDTAVYYCARQMGYWHFDLWGRGTLVTVSS
Light ChainEIVLTQSPATLSLSPGERATLSCRASQSVSSYLAWYQQKPGQAPRLLIYDASNRATGIPARFSGSGSGTDFTLTISSLEPEDFAVYYCQQRSNWPPLTFGGGTKVEIK
100% seqID Fv StructureNone
99% seqID Fv StructureNone
95-98% seqID Fv StructureNone
>   Metadata
FormatWhole mAb
IsotypeG1
Highest Clinical Trial (June '19)Phase-I/II
Estimated Status (June '19)Active
Recorded Developmental Technologyna
INN Year Proposed2010
INN Year Recommended2011
Companies InvolvedMedarex, NovImmune SA, Harvard Medical School, Tiziana Life Sciences
Conditions Approvedna
Conditions ActiveCrohn's disease, Neurodegenerative disorders, Primary biliary cirrhosis, Inflammatory bowel diseases, Non-alcoholic steatohepatitis, Type 2 diabetes mellitus
Conditions DiscontinuedTransplant rejection, Type 1 diabetes mellitus
Notes

SAbDab paper: Dunbar, J., Krawczyk, K. et al (2014). Nucleic Acids Res. 42. D1140-D1146 [link]

Thera-SAbDab paper: Raybould, M.I.J., Marks, C. et al (2019). Nucleic Acids Res. gkz827 [link]